News and Trends 13 Apr 2023 Aspect and Novo Nordisk working on bioprinted tissue for diabetes and obesity Aspect Biosystems and Novo Nordisk A/S are set to collaborate on developing bioprinted tissue therapeutics to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s background in stem cell differentiation […] April 13, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Adaptyv Bio launches to ‘change protein engineering’ AI tools like ChatGPT are revolutionizing how the world generates text, images and code. In a similar way, machine learning algorithms and generative AI are upending traditional processes in life sciences and collapsing time frames in drug discovery and materials development. AlphaFold by DeepMind is probably the most well-known machine learning model in this space. […] April 13, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Alentis Therapeutics raises $105M for claudin platform Alentis Therapeutics is a clinical-stage biotech developing treatments for organ fibrosis and claudin-1 (CLDN1) positive tumors. The company has announced $105 million in Series C financing. The funding round was led by Jeito Capital, Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 […] April 13, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Apr 2023 6 new vaccines being developed for difficult-to-treat diseases There are several promising new vaccine candidates being developed for complex diseases that historically have been extremely difficult to find treatments and cures for. The development of these new vaccines could eventually lead to breakthrough treatments for diseases such as Alzheimer’s disease, HIV, Parkinson’s disease, Lyme disease, and breast cancer. According to the World Health […] April 12, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 12 Apr 2023 New technique developed for safer gene editing CRISPR-Cas9 is widely used to edit the genome by studying genes of interest and modifying disease-associated genes. However, this process can be associated with potential side effects, including unwanted mutations and toxicity. Researchers at Kyushu University and Nagoya University School of Medicine in Japan have developed an optimized genome-editing method that vastly reduces mutations, opening […] April 12, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 PsychoGenics launches eCube AI platform for drug discovery PsychoGenics Inc. has launched eCube, a pharmaco-electroencephalography (pharmacoEEG) platform to support phenotypic drug discovery. The company said that unlike traditional target-based drug discovery, this technique can identify novel treatments with multiple targets. Similar to the company’s AI-enabled, behavior-based platform, SmartCube, eCube harnesses machine learning to identify central nervous system (CNS) penetrant compounds and predict their […] April 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 11 Apr 2023 Is a vaccine for Parkinson’s disease possible? Finding a truly effective treatment for Parkinson’s disease – that goes beyond simply managing symptoms – has long been a challenging task and, to this day, there are no available therapeutic options that can effectively slow or stop the underlying disease. However, research and trials to find treatments are ongoing and, as World Parkinson’s Day […] April 11, 2023 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, said the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for TP-1287, an investigational oral CDK9 inhibitor, for the treatment of Ewing sarcoma. “We are delighted to have received this designation for TP-1287 which underscores the need for additional treatment […] April 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 Calida Therapeutics launches to tackle thrombo-inflammatory disorders Calida Therapeutics, a preclinical stage biotech company specializing in thrombo-inflammatory disorders, has announced its incorporation in Paris, France. Calida Therapeutics has already raised €2 million ($2.17 million) in seed funding from venture capital company AdBio partners. The funds will be used to conduct additional in vivo proofs of concept and select a lead candidate. Calida […] April 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2023 Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M Vitarka Therapeutics, which focuses on non-viral drug delivery technology, has raised £1.27 million ($1.58 million) in equity from venture capital firm SOSV, the UK Innovation & Science Seed Fund (UK12S) and grant funding from Innovate UK. Founded in 2021 by Vineeta Tripathi, Vitarka Therapeutics is developing combination medicines using RNAi therapies and a non-viral drug […] April 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2023 InflaRx receives emergency use authorization for critically ill COVID-19 patients treatment InflaRx N.V., a German company developing anti-inflammatory therapeutics by targeting the complement system, has announced that Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adults. Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody that acts on […] April 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2023 Ginkgo Bioworks boosts gene therapy capacity with StrideBio asset acquisition Ginkgo Bioworks has acquired StrideBio’s adeno-associated virus (AAV) capsid discovery and engineering platform assets. A secondary close is scheduled upon the transfer of certain additional in-license agreements to Ginkgo Bioworks. Ginkgo Bioworks will incorporate the assets and IP into its end-to-end AAV gene therapy development platform, allowing the company’s customers to leverage new tools to […] April 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email